DELAFIELD, Wis. (Stockpickr) -- As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Pacific Drilling

Pacific Drilling  (PACD - Get Report) , together with its subsidiaries, operates as an offshore drilling contractor. This stock is trading up 2.5% $1.62 in Thursday's trading session.

  • Thursday's Range: $1.51-$1.62
  • 52-Week Range: $1.14-8.10
  • Thursday's Volume: 351,000
  • Three-Month Average Volume: 810,702

From a technical perspective, Pacific Drilling is spiking modestly higher here right above some key near-term support at its 20-day moving average of $1.46 a share with lighter-than-average volume. This stock has been uptrending over the last few weeks, with shares ripping higher off its 52-week low of $1.14 to its recent high of $1.76 a share. During that move, shares of Pacific Drilling have been making mostly higher lows and higher highs, which is bullish technical price action. That jump to the upside has now pushed this stock within range of triggering a big breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out its 50-day moving average of $1.71 to $1.76 a share and then once it clears more key resistance levels at $1.90 to $2.01 a share with high volume.

Traders should now look for long-biased trades in Pacific Drilling as long as it's trending above its 20-day moving average of $1.46 and then once it sustains a move or close above those breakout levels with volume that hits near or above 810,702 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $2.25 to $2.40, or even $2.80 a share.

Sorrento Therapeutics

Sorrento Therapeutics  (SRNE - Get Report) , a biopharmaceutical company, focuses on the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the U.S., Europe and internationally. This stock is trading up 7.2% to $8.42 in Thursday's trading session.

  • Thursday's Range: $7.82-$8.32
  • 52-Week Range: $3.41-$26.80
  • Thursday's Volume: 135,000
  • Three-Month Average Volume: 685,202

From a technical perspective, Sorrento Therapeutics is ripping sharply higher here right above some near-term support at $7.77 with lighter-than-average volume. This stock has been attempting to carve out a major bottoming chart pattern over the last few weeks, with shares finding some buying interest at $7.64, $7.83 and $7.77 a share. This potential bottom is coming after shares of Sorrento Therapeutics collapsed sharply off its July high of $26.80 to that recent low of $7.64 a share. This stock is now starting to rip higher off those support levels and it's quickly moving within range of triggering a big breakout trade. That trade will trigger if this stock manages to clear some key near-term overhead resistance levels at $8.93 to its 20-day moving average of $9.14 a share with high volume.

Traders should now look for long-biased trades in Sorrento Therapeutics as long as it's trending above those recent major support levels and then once it sustains a move or close above those breakout levels with volume that hits near or above 685,202 shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $11 to $11.50, or even its 50-day moving average of $12.11 a share.


Raptor Pharmaceuticals

Raptor Pharmaceuticals  (RPTP) , a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. This stock is trading up 8.1% to $5.66 in Thursday's trading session.

  • Thursday's Range: $5.23-$5.69
  • 52-Week Range: $5.17-$16.28
  • Thursday's Volume: 570,000
  • Three-Month Average Volume: 1.57 million

From a technical perspective, Raptor Pharmaceuticals is ripping sharply higher here right off its new 52-week low of $5.17 with lighter-than-average volume. This stock has been attempting to carve out a bottom over the last few weeks, with shares finding some buying interest at $5.45, $5.50 and now $5.17 a share. This strong spike to the upside on Thursday is now quickly pushing shares of Raptor Pharmaceuticals within range of triggering a major breakout trade above some key near-term overhead resistance levels. That breakout will trigger if this stock manages to take out its 20-day moving average of $6 and then once it clears more key near-term overhead resistance levels at $6.12 to $6.25 a share with high volume.

Traders should now look for long-biased trades in Raptor Pharmaceuticals as long as it's trending above those recent and potential major bottom support levels and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.57 million shares. If that breakout jumps off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $6.83 to $7, or even $7.50 to its gap-down-day high from September at around $9 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.